Last C$0.81 CAD
Change Today -0.01 / -1.22%
Volume 52.3K
As of 3:45 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONC) Snapshot

Open
C$0.82
Previous Close
C$0.82
Day High
C$0.88
Day Low
C$0.81
52 Week High
03/21/14 - C$2.31
52 Week Low
10/10/14 - C$0.45
Market Cap
72.5M
Average Volume 10 Days
69.8K
EPS TTM
C$-0.23
Shares Outstanding
89.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONC)

oncolytics biotech inc (ONC) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONC) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONC) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

Founded in 1998

oncolytics biotech inc (ONC) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: C$530.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: C$280.0K
Chief Operating Officer and Director
Total Annual Compensation: C$365.0K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: C$331.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $271.2K
Compensation as of Fiscal Year 2013.

oncolytics biotech inc (ONC) Key Developments

Oncolytics Biotech Inc. Announces Consolidated Earnings Results for Third Quarter and Nine Months Ended Sept. 30, 2014

Oncolytics Biotech Inc. announced consolidated earnings results for third quarter and nine months ended Sept. 30, 2014. For the quarter, the company reported operating loss of $4,677,213, loss before income taxes of $4,637,276, net loss of $4,636,608, net comprehensive loss of $4,536,147 or $0.05 per basic and diluted share cash used in operating activities of $4,415,215, acquisition of property and equipment of $113,782 compared to the operating loss of $6,224,129, loss before income taxes of $6,113,650, net loss of $6,113,650, net comprehensive loss of $6,147,163 or $0.07 per basic and diluted share cash used in operating activities of $6,509,872, acquisition of property and equipment of $103,512 for the same quarter a year ago. For the year to date, the company reported operating loss of $15,011,671, loss before income taxes of $14,833,494, net loss of $14,840,222, net comprehensive loss of $14,731,780 or $0.17 per basic and diluted share cash used in operating activities of $16,359,528, acquisition of property and equipment of $131,001 compared to the operating loss of $18,030,973, loss before income taxes of $17,740,167, net loss of $17,740,167, net comprehensive loss of $17,666,041 or $0.21 per basic and diluted share cash used in operating activities of $20,029,692, acquisition of property and equipment of $250,814 for the same period a year ago.

Oncolytics Biotech Inc. - Special Call

To discuss detailed data from the randomized Phase 2 study in pancreatic cancer (NCI-8601)

Oncolytics Biotech Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study

Oncolytics Biotech Inc. announced overall and KRAS-mutated patient data from a two-arm randomized phase 2 study of carboplatin, paclitaxel plus REOLYSIN (test arm) versus carboplatin and paclitaxel alone (control arm) in the first line treatment of patients with recurrent or metastatic pancreatic cancer (NCI-8601). The trial is sponsored by the U.S. National Cancer Institute (NCI) through a clinical trials agreement between the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis and Oncolytics. Oncolytics provided clinical supplies of REOLYSIN for the study and paid for the immune and genetic testing of the patients. The overall objectives of the study were to determine the progression free survival of the overall patient population and the patient population according to KRAS mutation status. The study enrolled 73 patients, 37 were in the control arm, 36 were in the test arm. The median progression free survival for the control arm was 5.16 months (95% confidence interval (CI) = 2.267 to 6.176) versus 5.26 months for the test arm (95% CI = 3.187 to 6.307). KRAS mutated patient population: As part of the study design, patients were screened for KRAS status at codon 12. Of the 60 patients where KRAS status could be determined (mutant versus wild type), 44 (73%) had mutations in the KRAS gene (n = 23 in the control arm, n = 21 in the test arm). Median progression free survival in the test arm was 5.72 months (95% CI = 3.187 to 6.767) versus 4.11 months in the control arm (95% CI = 1.938 to 6.176). This translates into a 1.61 month (39%) improvement in median progression free survival in the test arm versus the control arm. Three patients on the test arm and one on the control arm had not progressed as of the time of analysis. Kaplan-Meier plot of the Progression Free Survival (PFS) of the control arm versus the test arm of the KRAS mutated patient population.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONC:CN C$0.81 CAD -0.01

ONC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONC.
View Industry Companies
 

Industry Analysis

ONC

Industry Average

Valuation ONC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.